Aarti Drugs (NSE:AARTIDRUGS) E10: ₹21.21 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:AARTIDRUGS Aarti Drugs Ltd NSE:AARTIDRUGS
74 GF Score
Price ₹427.10
GF Value ₹511.14
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Aarti Drugs E10?

Aarti Drugs NSE:AARTIDRUGS +3.74% 74 E10 is ₹21.21 as of Jun. 2026. GuruFocus rates NSE:AARTIDRUGS with a GF Score™ of 74/100 and a GF Value™ of ₹511.14 (Modestly Undervalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Aarti Drugs's adjusted earnings per share data for the three months ended in Jun. 2026 was ₹5.490. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is ₹21.21 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Aarti Drugs's average E10 Growth Rate was 9.60% per year. During the past 3 years, the average E10 Growth Rate was 8.20% per year. During the past 5 years, the average E10 Growth Rate was 9.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Aarti Drugs was 11.30% per year. The lowest was 8.20% per year. And the median was 9.20% per year.

As of today (2026-09-02), Aarti Drugs's current stock price is ₹427.10. Aarti Drugs's E10 for the quarter that ended in Jun. 2026 was ₹21.21. Aarti Drugs's Shiller PE Ratio of today is 20.14.

During the past 13 years, the highest Shiller PE Ratio of Aarti Drugs was 82.50. The lowest was 16.38. And the median was 28.43.


Aarti Drugs  (NSE:AARTIDRUGS) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Aarti Drugs's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=427.10/21.21
=20.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Aarti Drugs was 82.50. The lowest was 16.38. And the median was 28.43.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Aarti Drugs E10 Related Terms


Aarti Drugs E10 Historical Data

* Premium members only.

The historical data trend for Aarti Drugs's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aarti Drugs E10 Chart

Aarti Drugs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.42 16.25 17.74 18.81 20.62

Aarti Drugs Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.34 19.91 20.17 20.62 21.21

NSE:AARTIDRUGS vs ZTS: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Aarti Drugs's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aarti Drugs Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aarti Drugs's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Aarti Drugs's Shiller PE Ratio falls into.


NSE:AARTIDRUGS
74GF Score
Aarti Drugs Ltd NSE:AARTIDRUGS
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aarti Drugs E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Aarti Drugs's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=5.49/167.3573*167.3573
=5.490

Current CPI (Jun. 2026) = 167.3573.

Aarti Drugs Quarterly Data

per share eps CPI Adj_EPS
201609 2.278 105.961 3.598
201612 1.890 105.196 3.007
201703 2.302 105.196 3.662
201706 1.193 107.109 1.864
201709 2.473 109.021 3.796
201712 2.445 109.404 3.740
201803 2.543 109.786 3.877
201806 2.455 111.317 3.691
201809 1.913 115.142 2.781
201812 2.215 115.142 3.219
201903 3.015 118.202 4.269
201906 2.390 120.880 3.309
201909 3.468 123.175 4.712
201912 2.980 126.235 3.951
202003 6.352 124.705 8.525
202006 9.170 127.000 12.084
202009 8.080 130.118 10.392
202012 7.300 130.889 9.334
202103 5.550 131.771 7.049
202106 5.250 134.084 6.553
202109 4.600 135.847 5.667
202112 6.290 138.161 7.619
202203 5.976 138.822 7.204
202206 3.757 142.347 4.417
202209 4.180 144.661 4.836
202212 3.961 145.763 4.548
202303 6.057 146.865 6.902
202306 5.167 150.280 5.754
202309 4.290 151.492 4.739
202312 3.990 152.924 4.367
202403 5.090 153.035 5.566
202406 3.620 155.789 3.889
202409 3.830 157.882 4.060
202412 4.060 158.323 4.292
202503 6.880 157.552 7.308
202506 5.910 159.755 6.191
202509 4.950 162.289 5.105
202512 4.440 163.281 4.551
202603 6.050 164.272 6.164
202606 5.490 167.357 5.490

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of ₹21.21 mean?
Aarti Drugs (NSE:AARTIDRUGS) has a E10 of ₹21.21 as of Jun. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Aarti Drugs and its competitors.
Is Aarti Drugs' E10 too high?
Aarti Drugs' current E10 is ₹21.21. Overall, Aarti Drugs has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aarti Drugs' E10 compare to ZTS?
Aarti Drugs' E10 of ₹21.21 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Aarti Drugs and its competitors. Aarti Drugs's current E10 is ₹21.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aarti Drugs stock overvalued right now?
Based on GuruFocus' analysis, Aarti Drugs (NSE:AARTIDRUGS) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹511.14, compared to a current price of ₹427.10 — trading 16.4% below its estimated fair value. The current E10 is ₹21.21. Aarti Drugs' overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Aarti Drugs (NSE:AARTIDRUGS), the current E10 is ₹21.21 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aarti Drugs (NSE:AARTIDRUGS) Overvalued in 2026?

Based on GuruFocus' analysis, Aarti Drugs stock appears to be undervalued. The current stock price of ₹427.10 is trading 16.4% below its estimated GF Value™ of ₹511.14. GuruFocus considers Aarti Drugs to be Modestly Undervalued.

Key valuation signals for NSE:AARTIDRUGS:

  • E10: ₹21.21
  • GF Value™: ₹511.14 vs. price of ₹427.10 (16.4% below fair value)
  • GF Score™: 74/100 with 3 warning signs

No single metric tells the full story. See the NSE:AARTIDRUGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Aarti Drugs Business Description

Other Exchanges 524348:India
Address Road No. 29, Plot Number 109-D, Mahendra Industrial Estate, Ground Floor, Sion (East), Mumbai, MH, IND, 400022
Aarti Drugs Ltd is a pharmaceutical company. It offers active pharmaceutical ingredients (APIs), pharma intermediaries, specialty chemicals, and formulations in a range of therapeutic categories, such as anti-inflammatory, cardioprotectant, antibiotic, antidiabetic, and vitamins among others. The product offerings of the company comprise Aceclofenac, Celecoxib, Moxifloxacin, and others. The firm caters to both domestic and international markets and derives a majority of its revenue from its business in India.
74GF Score

Get the complete analysis for NSE:AARTIDRUGS

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹427.10
Price
₹511.14
GF Value